---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001394"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:28:33.680621+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silexion partners with Catalent for siRNA formulation and manufacturing of SIL204

## Summary
- Collaboration with Catalent for SIL204 formulation development and clinical manufacturing at Limoges, France facility.
- SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic, colorectal, and lung cancers.
- Company plans to initiate human clinical trials for SIL204 in first half of 2026.
- Preclinical data showed significant reduction in primary tumor growth and metastatic spread in pancreatic cancer models.
- Regulatory submissions to Israel Ministry of Health expected H2 2025 and to EU in H1 2026.

## SEC filing metadata
- accession: 0001178913-25-001394
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/0001178913-25-001394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/zk2533046.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001394
- JSON: https://secwatch.observer/filing/0001178913-25-001394.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.